Fundraising FoxDeerfield Management Company — 2018 Investments
9 investments dated 2018 · listed companies and verified rows first · show all
Mirum Pharmaceuticals is a biopharmaceutical company that develops and delivers therapies for people living with rare diseases.
BiotechHealthtechSan Diego, US
Chris Peetz(Co-founder & Chief Executive Officer)inEric Bjerkholt(Executive Officer)inPeter Radovich(Executive Officer)in
BoardPatrick Heron(Director)inMichael Grey(Director)Timothy Walbert(Director)
Co-investorsChiesi VenturesFrazier Life SciencesLongitude CapitalMESA VERDE VENTURE PARTNERSNew Enterprise Associates (NEA)Pappas Capital+4 more
Dracen Pharmaceuticals is a private drug developer working at the intersection of cancer metabolism and immuno-oncology, developing glutamine antagonists that inhibit tumor glutamine metabolism and remodel the tumor microenvironment.
BiotechHealthtechBaltimore, US
Robert Wild(Co-founder & Chief Scientific Officer)Thomas M. Estok(Chief Executive Officer, President and Treasurer)Drew Pardoll, M.D., Ph.D.(Director)
BoardRobert Jackson(Director)
Board seatJonathan Leff· per SEC Form D
Co-investorsBiotech Investments S.R.Oi&i Biotech FundOUP (Osage University Partners)Sofinnova Ventures
BiotechCambridge, US
Geoff McDonoughy(Executive Officer, Director)Glenn Goddard(Executive Officer)Mark Angelino(Executive Officer)
BoardJason Rhodes(Director)inCatherine Stehman-Breen(Director)Anthony Quinn(Director)
Co-investorsAtlas VentureForesite CapitalWellington ManagementCasdin CapitalF-Prime CapitalFidelity Investments+1 more
San Diego clinical-stage biopharma developing non-bile acid FXR agonists for liver and gastrointestinal diseases.
BiotechSan Diego, US
Ronald Evans(Director)Trisha Millican(Executive Officer)Ken Song(Executive Officer, Director)
BoardKristina Burow(Director)inRichard Heyman(Director)inAmir Nashat(Director)in
Co-investorsage1EcoR1 CapitalLAVLifeSci Venture PartnersLilly Asia VenturesNew Enterprise Associates (NEA)+8 more
Strata Oncology develops precision oncology biomarkers and predictive diagnostic tools for cancer treatment, including treatment response scores for antibody-drug conjugates (ADCs) and an Immunotherapy Response Score for anti-PD-1/PD-L1 therapies.
AI & Machine LearningBiotechDigital HealthMedical DevicesAnn Arbor, US
Daniel Rhodes(Executive Officer, Director)Dan Rhodes(Founder)inScott Tomlins(Founder)inMatthew Martin(Executive Officer)Jeffrey Williams(Executive Officer, Director)
BoardChristopher O'Donnell(Director)in
Co-investorsArboretum VenturesBaird CapitalMerck Global Health Innovation FundMSD Global Health Innovation FundPfizer Venture InvestmentsWellington Management+1 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Iowa ApproachPairwise PlantsV-Wave
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.